和黃醫藥(00013.HK)續漲一成曾逼近68元 胰腺藥上市申請獲歐洲EMA確認受理
和黃醫藥(00013.HK)旗下胰腺新藥上市申請繼月初獲美國FDA受理後,歐洲EMA也確認其上市申請,該股承昨天回升逾半成重越10天線(58.5元)後,今天曾進一步漲12%高見67.95元,現造66.7元,續漲10%,成交續增至249萬股,涉資1.61億元。
和黃醫藥公佈,歐洲藥品管理局(EMA)已確認並受理索凡替尼用於治療胰腺和胰腺外(非胰腺)神經內分泌瘤(NET)的上市許可申請,並已確認所提交材料的完整性及已準備好啓動正式審評程序。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.